Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
10:00am, Thursday, 18'th Sep 2025
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO).
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
05:49am, Thursday, 18'th Sep 2025
LOS ANGELES , Sept. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agios Pharmaceutic
AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm
12:20pm, Monday, 15'th Sep 2025
LOS ANGELES--(BUSINESS WIRE)---- $AGIO--AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
12:30pm, Saturday, 13'th Sep 2025
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO
02:20pm, Wednesday, 10'th Sep 2025
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such inves
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO
03:00pm, Monday, 08'th Sep 2025
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO).
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
11:05am, Friday, 05'th Sep 2025
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated
12:46pm, Thursday, 04'th Sep 2025
Agios Pharmaceuticals, Inc. faces a three-month FDA review delay for mitapivat in thalassemia due to safety concerns, but no new efficacy or safety data was requested. Despite the setback, I remain co
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use
10:49am, Thursday, 04'th Sep 2025
On Thursday, the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for Agios Pharmaceuticals, Inc.'s AGIO supplemental New Drug Application (sNDA) o
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
07:00am, Thursday, 04'th Sep 2025
PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
04:01pm, Monday, 04'th Aug 2025
Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia
Agios (AGIO) Q2 Revenue Jumps 45%
04:49pm, Friday, 01'st Aug 2025
Agios Pharmaceuticals (AGIO -6.15%), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable reven
Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript
05:02pm, Thursday, 31'st Jul 2025
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Brian M. Goff - CEO & Director Cecilia Jones - Chief Financial Officer Sarah Gheuens - Ch
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
08:40am, Thursday, 31'st Jul 2025
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.93 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to a loss of $1.69 per share a year ago.
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
06:30am, Thursday, 31'st Jul 2025
$12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securities PYRUKYND sNDA for thalassemia un
